News | April 03, 2026
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
This marks a meaningful step in the company's continued expansion in the region
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Subscribe To Our Newsletter & Stay Updated
